参·考·文·献

［1］Marjot T，Moon AM，Cook JA，et al.Outcomes following SARS-CoV-2 infection in patients with chronic liver disease：an international registry study［J］.J Hepatol，2021，74（3）：567-577.

［2］Efe C，Dhanasekaran R，Lammert C，et al.Outcome of COVID-19 in patients with autoimmune hepatitis：an international multicenter study［J］.Hepatology，2021，73（6）：2099-2109.

［3］Marjot T，Buescher G，Sebode M，et al.SARS-CoV-2 infection in patients with autoimmune hepatitis［J］.J Hepatol，2021，74（6）：1335-1343.

［4］Lleo A，Invernizzi P，Lohse AW，et al.Management of patients with autoimmune liver disease during COVID-19 pandemic［J］.J Hepatol，2020，73（2）：453-455.(https://www.daowen.com)

［5］Xu W，Huang C，Fei L，et al.Dynamic changes in liver function tests and their correlation with illness severity and mortality in patients with COVID-19：a retrospective cohort study［J］.Clin Interv Aging，2021，16：675-685.

［6］Li Q，Li W，Jin Y，et al.Efficacy evaluation of early，low-dose，short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia：a retrospective cohort study［J］.Infect Dis Ther，2020，9（4）：823-836.

［7］Horby P，Lim WS，Emberson JR，et al.Dexamethasone in hospitalized patients with Covid-19［J］.N Engl J Med，2021，384（8）：693-704.